LEADER 02328nam  2200601 a 450 
001 9910778793703321
005 20230421033142.0
010   $a1-280-19602-5
010   $a9786610196029
010   $a0-309-59835-4
010   $a0-585-02478-2
035   $a(CKB)110986584751352
035   $a(SSID)ssj0000123477
035   $a(PQKBManifestationID)11143357
035   $a(PQKBTitleCode)TC0000123477
035   $a(PQKBWorkID)10005859
035   $a(PQKB)10618493
035   $a(MiAaPQ)EBC3376668
035   $a(Au-PeEL)EBL3376668
035   $a(CaPaEBR)ebr10056944
035   $a(OCoLC)923265433
035   $a(EXLCZ)99110986584751352
100   $a19931027d1993      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aClinical applications of mifepristone (RU 486) and other antiprogestins$b[electronic resource] $eassessing the science and recommending a research agenda /$fCommittee on Antiprogestins: Assessing the Science, Division of Health Promotion and Disease Prevention, Institute of Medicine ; Molla S. Donaldson ... [et al.], editors
210   $aWashington, D.C. $cNational Academy Press$d1993
215   $axi, 288 p. $cill
300   $a"Support for this project was provided by a grant from the Henry J. Kaiser Family Foundation, Menlo Park, California."--Verso T.p.
300   $aCommittee chairman: Leslie Z. Benet.
311   $a0-309-04949-0 
320   $aIncludes bibliographical references and index.
606   $aMifepristone$xResearch
606   $aAbortifacients$xResearch
606   $aProgesterone$xAntagonists$xResearch
615  0$aMifepristone$xResearch.
615  0$aAbortifacients$xResearch.
615  0$aProgesterone$xAntagonists$xResearch.
676   $a615/.766
701   $aBenet$b Leslie Z$096362
701   $aDonaldson$b Molla S$01506301
712 02$aInstitute of Medicine (U.S.).$bCommittee on Antiprogestins: Assessing the Science.
712 02$aInstitute of Medicine (U.S.).$bDivision of Health Promotion and Disease Prevention.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910778793703321
996   $aClinical applications of mifepristone (RU 486) and other antiprogestins$93762829
997   $aUNINA